Jazz generated total revenue of nearly $1.1 billion in the first quarter, up 19% from the prior-year period. Key sleep disorder drug Xywav posted $408 million in sales and added 425 new patients in the quarter. Jazz reaffirmed its 2026 total sales guidance of roughly $4.4 billion at the midpoint.
The GW acquisition allows Jazz to reach patient populations with rare and severe forms of epilepsy with approved indications for Epidiolex as young as 1 year of age.
Jazz will face branded competition from Wakix and Lumryz, in addition to generic pressure, which will likely erode Jazz's patient share.
|
Metric
|
JAZZ
|
IONS
|
GMAB
|
|---|---|---|---|
Price/Earnings (Normalized) | 9.74 | — | 14.71 |
Price/Book Value | 3.27 | 24.92 | 2.66 |
Price/Sales | 3.31 | 11.27 | 4.01 |
Price/Cash Flow | 9.11 | — | 18.08 |
|
Metric
|
JAZZ
|
IONS
|
GMAB
|
|---|---|---|---|
Quick Ratio | 1.65 | 2.78 | 2.17 |
Current Ratio | 2.04 | 4.10 | 2.18 |
Interest Coverage | −0.21 | −2.91 | 6.45 |
|
Metric
|
JAZZ
|
IONS
|
GMAB
|
|---|---|---|---|
Return on Assets (Normalized) | 8.03% | −5.69% | 12.45% |
Return on Equity (Normalized) | 22.25% | −33.26% | 20.24% |
Return on Invested Capital (Normalized) | 11.29% | −5.13% | 14.93% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Llkvstdg | Trjkvqf | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Rkkqxlg | Dmdwdz | $64B | |||
| argenx SE ADR
ARGX
| Pqjrrjdh | Dkw | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Scjbzxjf | Fvgdj | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Mskxvbhjs | Ljppys | $24B | |||
| BioNTech SE ADR
BNTX
| Smwywsfbl | Jdgs | $23B | |||
| Incyte Corp
INCY
| Fhshtvwk | Mxqbd | $22B | |||
| Moderna Inc
MRNA
| Sxxpfvtp | Mrc | $20B | |||
| BridgeBio Pharma Inc
BBIO
| Hzvcbys | Fwjv | $13B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
United States